Research Grade Anti-Human F8 (TB-402)

Catalog No.

DHB86201

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG

Clonality

Monoclonal

Applications

Research Grade Biosimilar

Target

AHF, Procoagulant component, Coagulation factor VIII, Antihemophilic factor, F8C, F8

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P00451

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

TB-402, TB 402, TB402

Clone ID

TB-402

Note

For research use only. Not suitable for clinical or therapeutic use.

Tolerability and pharmacokinetics of TB-402 in healthy male volunteers., PMID:20637972

New parenteral anticoagulants in development., PMID:21045018

Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial., PMID:21284801

Partial versus complete factor VIII inhibition in a mouse model of venous thrombosis., PMID:21777952

Antidote strategies to reverse anticoagulation with TB-402, a long-acting partial inhibitor of factor VIII., PMID:22540161

Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial., PMID:23615791

TB-402 for the prevention of venous thromboembolism in orthopaedic surgery: something new and promising, or not?, PMID:23677042

Document Download

Research Grade Anti-Human F8 (TB-402).pdf